Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cyclophosphamide
Drug ID BADD_D00549
Description Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Indications and Usage Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
Marketing Status approved; investigational
ATC Code L01AA01
DrugBank ID DB00531
KEGG ID D00287; D07760
MeSH ID D003520
PubChem ID 2907
TTD Drug ID D0CT9C
NDC Product Code 14335-360; 38779-0506; 10019-944; 10019-945; 10019-984; 58623-0024; 62559-931; 70121-1240; 0781-3233; 0781-3244; 10019-955; 51927-4871; 71052-223; 81955-0004; 43598-662; 50742-520; 69097-517; 70121-1239; 72572-085; 72572-087; 0781-3255; 10019-935; 10019-942; 51927-0221; 76339-191; 62332-619; 70121-1238; 54879-022; 55150-271; 62332-618; 69097-516; 70860-218; 42973-318; 10019-937; 76339-164; 50742-519; 51407-748; 72603-411; 10019-939; 65124-0003; 50742-521; 54879-021; 68001-564; 72603-326; 16714-857; 43598-661; 55150-270; 0054-0382; 10019-956; 10019-957; 51407-749; 51407-750; 68001-565; 0054-0383; 72572-083; 15308-0921; 10019-936; 57821-004; 16714-859; 68001-442; 68001-444; 72603-104; 10019-982; 82920-708; 16714-858; 46708-618; 68001-443; 10019-938; 10019-943; 57884-0022; 68554-0062; 43598-660; 46708-619
UNII 8N3DW7272P
Synonyms Cyclophosphamide | Sendoxan | B-518 | B 518 | B518 | Cyclophosphamide Anhydrous | Cyclophosphamide, (R)-Isomer | Cyclophosphamide, (S)-Isomer | Cytophosphane | Cyclophosphamide Monohydrate | Cytophosphan | Cytoxan | Endoxan | Neosar | NSC-26271 | NSC 26271 | NSC26271 | Procytox | (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate | Cyclophosphane
Chemical Information
Molecular Formula C7H15Cl2N2O2P
CAS Registry Number 50-18-0
SMILES C1CNP(=O)(OC1)N(CCCl)CCCl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Metastatic neoplasm16.16.01.007--Not Available
Neoplasm progression16.16.02.005--Not Available
Spinal cord disorder17.10.01.010--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Ill-defined disorder08.01.03.049--Not Available
Adverse drug reaction08.06.01.009--Not Available
Disease recurrence08.01.03.050--Not Available
Pulmonary toxicity12.03.01.013; 22.01.02.007--Not Available
Pigmentation disorder23.05.03.001--Not Available
Venoocclusive disease24.03.02.016--Not Available
Renal impairment20.01.03.010--Not Available
Muscle contracture15.03.05.024--Not Available
Carditis02.11.03.001--Not Available
Cystitis noninfective20.03.02.001--
Gene mutation03.20.03.001--Not Available
Bone marrow failure01.03.03.005--
Ureteric haemorrhage24.07.07.001; 20.06.01.003--Not Available
Organising pneumonia22.01.02.008--Not Available
Renal cell carcinoma20.01.04.003; 16.08.02.002--Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.004--
Acute kidney injury20.01.03.016--
Wound healing normal13.15.01.034--Not Available
Microsomia08.01.03.056--Not Available
Posterior reversible encephalopathy syndrome17.13.02.007--
Granulomatosis with polyangiitis24.12.04.011; 22.01.01.015; 20.05.01.013; 10.02.02.018--Not Available
Noninfective sialoadenitis07.06.04.003--Not Available
Multiple organ dysfunction syndrome08.01.03.057--
Myeloproliferative neoplasm16.21.03.006; 01.13.03.006--Not Available
Cross sensitivity reaction10.01.01.036--Not Available
Heavy menstrual bleeding21.01.03.005--Not Available
The 10th Page    First    Pre   10 11    Next   Last    Total 11 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene